Home DoYCan Health Completes Angel Funding Round to Advance Full-Course SaaS Rehabilitation Platform for Stroke Patients

DoYCan Health Completes Angel Funding Round to Advance Full-Course SaaS Rehabilitation Platform for Stroke Patients

Jun 13, 2022 08:00 CST Updated 08:00

VCBeat has learned that Jianerkang Technology Information Services (Guangzhou) Co., Ltd. (hereinafter referred to as “Dongyou Tech”) recently completed its angel round of financing, led byFuhui Venture Capital exclusively led the round, with the existing shareholder team continuing to participate in the follow-on investment.

 

Dongyou Technology, established in 2017, has long been dedicated to the development and application of a SaaS platform for comprehensive, whole-course rehabilitation management of stroke patients based on integrated remote rehabilitation. The company has launched the “Dongyou” Digital Rehabilitation Solution System, leveraging the application of digital therapeutics in motor rehabilitation.A mobile app-based approach is adopted to implement a three-tier rehabilitation medical service system comprising “tertiary hospitals + community health service stations + homes,” providing full-course rehabilitation management services for patients with mobility impairments, such as those with stroke, across both in-hospital and out-of-hospital settings.

 

Dongyou Technology also custom-develops physician-facing apps (for rehabilitation physicians, rehabilitation therapists, nurses, and community health stations) and patient-facing apps for partner healthcare institutions.

 

In April 2021, Dongyou Technology joined forces withInternet Hospital of Shunde Hospital Affiliated to Jinan UniversityLaunched and rolled out the "Remote Rehabilitation" service, which provides long-term rehabilitation treatment for discharged patients through medical consortium rehabilitation teams composed of "rehabilitation physicians + rehabilitation therapists + nurses" from the Department of Rehabilitation Medicine at tertiary hospitals, addressing the challenge of lack of rehabilitation guidance for mobility-impaired patients, such as those with stroke, after they return home.

 

The solution applications provided by Dongyou Technology are divided into two scenarios: in-hospital and out-of-hospital.


Patient Hospitalization, customized and delivered by the rehabilitation team, including rehabilitative exercises, health education, and home-based rehabilitation training plans for post-discharge care;

After the Patient Returns to the Community, patients may choose to continue receiving in-person rehabilitation therapy at community health service stations, or opt for home-based rehabilitation or tele-rehabilitation services.


Regardless of the rehabilitation modality, patients’ rehabilitation treatment plans are remotely assessed and formulated by the Department of Rehabilitation Medicine at tertiary hospitals, enabling patients to continue receiving ongoing rehabilitation therapy under the most professional and authoritative guidance after discharge.

 

The Notice on Launching the Action to Enhance Community-Based Integration of Medical and Elderly Care Services, recently issued by the National Health Commission in conjunction with eight other departments, points out that: Information technology levels in primary healthcare institutions should be improved; telemedicine service systems may be established relying on upper-level hospitals within medical consortia; and smart home- and community-based health and elderly care services may be explored through information technologies such as the internet. Support shall be provided to medical institutions for delivering integrated medical and elderly care services; comprehensive assessments of older adults’ functional capacity shall be conducted in a unified manner through mechanisms such as government procurement of services; and effective outcomes shall be achieved in the action to enhance community-based integration of medical and elderly care services.

 

Dongyou Technology’s solutions enable the rapid deployment and provision of whole-course rehabilitation management services for stroke patients across China’s healthcare institutions, establishing a three-tier rehabilitation network comprising “tertiary hospitals + community health stations + home care.” This model ensures that patients receive continuous professional rehabilitation services both in-hospital and out-of-hospital, while addressing the shortages of rehabilitation resources and clinical experience at community health service stations, thereby enhancing the rehabilitation skills, proficiency, and expertise of healthcare professionals at primary care institutions.


Remote rehabilitation breaks the temporal, spatial, and geographical constraints of rehabilitative therapy.Dongyou Technology’s early-stage pilot project was selected for the “Typical Cases of Innovative Applications of Emerging Technologies in Hospitals in 2021,” evaluated by the Chinese Hospital Association., in addition, a report on the pricing of remote rehabilitation services has been submitted to the Healthcare Security Administration for inclusion in the medical service fee schedule.

 

Dongyou Technology’s benchmark company is BlueJay Mobile Health, a California-based digital therapeutics enterprise founded in 2014. Since its inception, BlueJay has secured five rounds of financing. The company has launched a SaaS platform for remote rehabilitation and out-of-hospital management, which encompasses five core functionalities: telemedicine and information exchange, adherence management, treatment planning, therapeutic interventions, and home-based rehabilitation. Through BlueJay’s digital health solutions, patients are enabled to actively participate in and stay motivated to continue their rehabilitation plans at home, ultimately achieving better clinical outcomes.

 

Following this round of financing, Dongyou Technology will collaborate with tertiary hospitals and community health service stations to further advance and refine the construction of a three-tier networked rehabilitation medical service system integrated with tele-rehabilitation. This initiative aims to achieve comprehensive, whole-course rehabilitation management and services for stroke patients, thereby benefiting numerous patients and their families.

 

China currently has more than 2,900 tertiary hospitals and over 35,000 community health service stations. By leveraging digital rehabilitation methods, these institutions are working to establish a comprehensive, whole-course rehabilitation management and service system for stroke patients that integrates “hospital + community + home.” Additionally, the challenge of home-based rehabilitation is being addressed by training “home rehabilitation therapists.” Dongyou Technology’s solutions provide new approaches and directions for building China’s innovative three-tier rehabilitation medical service system, as well as for implementing home-based rehabilitation and nursing care. These efforts play a positive role in reducing disability rates among patients and improving rehabilitation success rates, indicating broad market application prospects.

 

>>>>

About Fuhui Venture Capital


Fuhui Venture Capital is a venture capital firm dedicated to the commercialization of scientific and technological achievements and early-stage investment in technology enterprises. It specializes in investments in sectors such as healthcare and advanced manufacturing, with a management team possessing extensive experience in both real-economy industries and equity investment. Its healthcare portfolio includes numerous high-quality companies, such as New Horizon Health (06606.HK), Airdoc Technology (02251.HK), Weizhen Biotechnology [medical devices], Jinbaihui Biotechnology [medical devices], Casecade [new drug R&D], Zhiben Pharmaceuticals [new drug R&D], Niulan Biotechnology [exosomes], Huazi Biotechnology [long-acting proteins], Baiji Hongye [new drug R&D], Youli Pharmaceuticals [new drug R&D], Luoqi Biotechnology [nanobodies], Lingkang Times [pharmaceutical CDMO], Ruishun Biotechnology [cell therapy], Xinling Pharmaceuticals [transdermal formulations], and Hengsai Biotechnology [cell therapy].